pith. sign in

arxiv: 2606.26659 · v1 · pith:75FU2IFBnew · submitted 2026-06-25 · 🧬 q-bio.QM

pVACtools v6: A comprehensive suite for neoantigen prediction, visualization, and therapy design

My H. Hoang , Susanna Kiwala , Megan Richters , Luke Hendrickson , Huiming Xia , Evelyn Schmidt , Christopher A. Miller , Kelsy C. Cotto
show 18 more authors
Cheryl F. Lichti Zach Skidmore Kartik Singhal Jennie X. Yao Jinglun Li Mariam Khanfar Isabel Risch Jeffrey Ward Ramaswamy Govindan Gavin Dunn Tanner M Johanns S. Peter Goedegebuure Todd A Fehniger Rachel Karchin Robert D. Schreiber William Gillanders Obi L. Griffith Malachi Griffith
This is my paper

Pith reviewed 2026-06-26 02:17 UTC · model grok-4.3

classification 🧬 q-bio.QM
keywords neoantigen predictioncancer vaccine designpVACtoolscis-splicing mutationsimmunotherapypersonalized medicinecomputational biologynoncanonical neoantigens
0
0 comments X

The pith

pVACtools v6 adds modules for neoantigens from cis-splicing mutations and noncanonical sources plus improved vaccine design tools.

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The paper describes eight major updates to the open-source pVACtools suite for neoantigen prediction and therapy design. These include new modules for quality assessment, cis-splicing mutations, and noncanonical sources, along with better selection strategies, a faster pVACvector algorithm, utilities for synthetic long peptides, support for additional species, and a comparison tool. The updates aim to cover the full workflow from basic discovery through personalized cancer vaccine design. A reader would care because neoantigen vaccines are advancing in clinical trials and need reliable computational support to identify and prioritize targets.

Core claim

pVACtools v6 expands quality and safety assessment with features such as peptide presentation scoring, immunogenicity prediction, anchor residue analysis, reference proteome similarity checks, and percentile scoring. It adds pVACsplice for neoantigens from tumor-specific cis-splicing mutations, pVACbind for noncanonical sources, improved neoantigen selection, a substantially improved pVACvector with higher DNA/mRNA vaccine design success rates and shorter runtimes, utilities for synthetic long peptide vaccines, extended prediction support for non-human species, and pVACcompare for comparing pVACseq results. These changes reinforce the suite as the most comprehensive toolkit for neoantigen re

What carries the argument

The pVACtools software suite with its new pVACsplice and pVACbind modules that handle additional sources of neoantigens beyond standard mutations.

If this is right

  • Researchers gain the ability to predict and prioritize neoantigens that arise from cis-splicing mutations in tumors.
  • Vaccine design success rates increase because the updated pVACvector algorithm produces more viable DNA or mRNA constructs in less time.
  • Users can now compare results from two separate pVACseq runs to evaluate different prediction settings or tumor samples.
  • Design of synthetic long peptide vaccines is supported by dedicated new utilities.
  • Prediction capabilities extend to many non-human species for preclinical studies.

Where Pith is reading between the lines

These are editorial extensions of the paper, not claims the author makes directly.

  • If the new modules prove reliable in practice, clinical pipelines could incorporate splicing-derived neoantigens as additional vaccine targets.
  • The suite's expansion might enable direct head-to-head testing of different neoantigen sources within the same workflow.
  • Extension to non-human species could support comparative oncology studies that test whether human-derived prediction rules hold in animal models.
  • Routine use of pVACcompare could reveal systematic differences in neoantigen calls across patient cohorts or sequencing platforms.

Load-bearing premise

The newly added modules for cis-splicing mutations and noncanonical sources produce accurate and useful neoantigen predictions.

What would settle it

Running pVACsplice and pVACbind on tumor samples with known experimentally validated neoantigens from splicing or noncanonical origins and checking whether the predictions match mass spectrometry or T-cell response data.

read the original abstract

With the rise of checkpoint blockade therapies and neoantigen-based vaccines reaching later-stage trials, there is a growing need for computational tools to identify and prioritize neoantigens. pVACtools, initially introduced in 2016, is an open-source informatic suite designed to support basic and translational neoantigen research. pVACtools assists prediction, prioritization, and visualization of neoantigens, as well as design of neoantigen-based therapies. We describe several major advances to pVACtools since the last update: (1) expanded neoantigen quality and safety assessment features, including support for peptide presentation scoring, immunogenicity prediction, anchor residue analysis, reference proteome similarity, percentile score calculation; (2) addition of pVACsplice, a new tool for predicting neoantigens from tumor-specific cis-splicing mutations; (3) addition of pVACbind, a flexible tool that supports noncanonical neoantigen sources; (4) improvement in neoantigen selection strategies; (5) a substantially improved pVACvector algorithm that achieves higher DNA/mRNA vector vaccine design success rates with shorter runtimes; (6) new utilities to support synthetic long peptide vaccine design; (7) extended prediction support for many non-human species; and (8) addition of pVACcompare, a tool to support comparison between two pVACseq results. Together, these updates reinforce pVACtools as the field's most comprehensive toolkit for neoantigen research, from basic discovery to the design and execution of personalized cancer vaccine clinical trials.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, simulated authors' rebuttal, and a circularity audit. Tearing a paper down is the easy half of reading it; the pith above is the substance, this is the friction.

Referee Report

2 major / 0 minor

Summary. The manuscript describes version 6 of the open-source pVACtools suite for neoantigen prediction, prioritization, visualization, and therapy design. It enumerates eight major advances since the prior release: expanded quality and safety assessment features (peptide presentation scoring, immunogenicity prediction, anchor residue analysis, reference proteome similarity, and percentile scoring); new modules pVACsplice (for cis-splicing mutations) and pVACbind (for noncanonical neoantigen sources); improved neoantigen selection strategies; a substantially revised pVACvector algorithm; utilities for synthetic long peptide vaccine design; extended support for non-human species; and the new pVACcompare tool. The authors conclude that these changes reinforce pVACtools as the field's most comprehensive toolkit spanning basic discovery to clinical trial design.

Significance. If the new modules and algorithmic improvements are shown to be accurate and practically useful, the update would be a significant contribution to the neoantigen field by extending an established open-source platform to previously unsupported mutation classes and sources, thereby lowering barriers for researchers working on personalized cancer vaccines.

major comments (2)
  1. [Abstract] Abstract: The central claim that the updates 'reinforce pVACtools as the field's most comprehensive toolkit' is load-bearing on the new pVACsplice and pVACbind modules producing accurate and useful predictions, yet the manuscript supplies no validation data, benchmark comparisons, accuracy metrics, or performance results on real or synthetic tumor datasets for either module.
  2. [Abstract] Abstract, item (5): The statement that the improved pVACvector 'achieves higher DNA/mRNA vector vaccine design success rates with shorter runtimes' is presented without any quantitative benchmarks, success-rate numbers, runtime comparisons, or test datasets to support the claimed improvement.

Simulated Author's Rebuttal

2 responses · 0 unresolved

We thank the referee for their review and constructive comments on our manuscript describing pVACtools v6. We address each major comment below and propose revisions where appropriate.

read point-by-point responses

  1. Referee: [Abstract] Abstract: The central claim that the updates 'reinforce pVACtools as the field's most comprehensive toolkit' is load-bearing on the new pVACsplice and pVACbind modules producing accurate and useful predictions, yet the manuscript supplies no validation data, benchmark comparisons, accuracy metrics, or performance results on real or synthetic tumor datasets for either module.

    Authors: We agree that the manuscript is a software description and update paper rather than a validation study. No new benchmark or accuracy data for pVACsplice or pVACbind are included, as these modules implement extensions based on established splicing and binding prediction approaches already validated in the literature. The claim of comprehensiveness refers to the expanded scope of supported neoantigen sources and workflows, not to new empirical performance results presented here. We will revise the abstract to qualify this statement, emphasizing the breadth of features while removing any implication that the new modules have been validated within this manuscript. revision: yes

  2. Referee: [Abstract] Abstract, item (5): The statement that the improved pVACvector 'achieves higher DNA/mRNA vector vaccine design success rates with shorter runtimes' is presented without any quantitative benchmarks, success-rate numbers, runtime comparisons, or test datasets to support the claimed improvement.

    Authors: The pVACvector improvements described are the result of algorithmic refactoring and optimization during development. However, we acknowledge that the manuscript provides no quantitative benchmarks, success rates, or runtime comparisons to support the specific performance claims. We will revise the abstract to remove the unsubstantiated performance assertions and describe the algorithmic changes in more neutral terms. revision: yes

Circularity Check

0 steps flagged

No circularity: descriptive software update without derivations or fitted predictions

full rationale

The manuscript is a descriptive update to pVACtools listing new features (pVACsplice, pVACbind, etc.) and asserting comprehensiveness. No equations, derivations, parameter fits, or predictive models appear anywhere in the text. The central claim of being the 'most comprehensive toolkit' is an assertion of feature coverage rather than a result derived from prior steps or self-citations. Self-citation of the 2016 introduction exists but is not load-bearing for any derivation. No patterns from the enumerated circularity kinds are present.

Axiom & Free-Parameter Ledger

0 free parameters · 0 axioms · 0 invented entities

This is a software description paper. It introduces no mathematical models, fitted parameters, axioms, or new theoretical entities.

pith-pipeline@v0.9.1-grok · 5934 in / 932 out tokens · 30411 ms · 2026-06-26T02:17:33.487499+00:00 · methodology

discussion (0)

Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.

Reference graph

Works this paper leans on

80 extracted references · 5 canonical work pages

  1. [1]

    Hundal, J. et al. pVACtools: A Computational Toolkit to Identify and Visualize Cancer Neoantigens. Cancer Immunol Res 8 , 409–420 (2020)

    2020

  2. [2]

    Xie, N. et al. Neoantigens: promising targets for cancer therapy. Signal Transduction and Targeted Therapy 8 , 9 (2023)

    2023

  3. [3]

    Carreno, B. M. et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348 , 803–808 (2015)

    2015

  4. [4]

    Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547 , 217–221 (2017)

    2017

  5. [5]

    Ott, P. A. et al. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell 183 , 347–362.e24 (2020)

    2020

  6. [6]

    Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403 , 632–644 (2024)

    2024

  7. [7]

    Sarnaik, A. A. et al. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. J Clin Oncol 39 , 2656–2666 (2021)

    2021

  8. [8]

    Schoenfeld, A. J. et al. Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors. Cancer Discov 14 , 1389–1402 (2024)

    2024

  9. [9]

    Lowery, F. J. et al. Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial. Nat Med 31 , 1994–2003 (2025)

    1994

  10. [10]

    C., Purvis, I

    Santiago, T. C., Purvis, I. J., Bettany, A. J. & Brown, A. J. The relationship between mRNA stability and length in Saccharomyces cerevisiae. Nucleic Acids Res 14 , 8347–8360 (1986)

    1986

  11. [11]

    Wayment-Steele, H. K. et al. Theoretical basis for stabilizing messenger RNA through secondary structure design. Nucleic Acids Res 49 , 10604–10617 (2021)

    2021

  12. [12]

    Cheng, F. et al. Research Advances on the Stability of mRNA Vaccines. Viruses 15 , (2023)

    2023

  13. [13]

    Flotte, T. R. Size does matter: overcoming the adeno-associated virus packaging limit. Respir Res 1 , 16–18 (2000)

    2000

  14. [14]

    Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618 , 144–150 (2023)

    2023

  15. [15]

    Yewdell, J. W. & Bennink, J. R. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 17 , 51–88 (1999)

    1999

  16. [16]

    Dudley, M. E. & Roopenian, D. C. Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens. J Exp Med 184 , 441–447 (1996)

    1996

  17. [17]

    Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348 , 69–74 (2015)

    2015

  18. [18]

    Y., Goedegebuure, S

    Chen, I., Chen, M. Y., Goedegebuure, S. P. & Gillanders, W. E. Challenges targeting cancer neoantigens in 2021: a systematic literature review. Expert Rev Vaccines 20 , 827–837 (2021)

    2021

  19. [19]

    McCarron, M. J. et al. Cross-competition shapes CD8+ T cell hierarchies and differentiation after RNA vaccination. Immunology (2025)

    2025

  20. [20]

    & Schrörs, B

    Lang, F., Riesgo-Ferreiro, P., Löwer, M., Sahin, U. & Schrörs, B. NeoFox: annotating neoantigen candidates with neoantigen features. Bioinformatics 37 , 4246–4247 (2021)

    2021

  21. [21]

    Zhou, C. et al. pTuneos: prioritizing tumor neoantigens from next-generation sequencing data. Genome Med 11 , 67 (2019)

    2019

  22. [22]

    Vensko, S. P. et al. LENS: Landscape of Effective Neoantigens Software. Bioinformatics 39 , (2023)

    2023

  23. [23]

    Hundal, J. et al. pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens. Genome Med 8 , 11 (2016)

    2016

  24. [24]

    Freed-Pastor, W. A. et al. The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer Cell 39 , 1342–1360.e14 (2021)

    2021

  25. [25]

    Westcott, P. M. K. et al. Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer. Nat Cancer 2 , 1071–1085 (2021)

    2021

  26. [26]

    Zhang, M. et al. Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. Nat Commun 12 , 1751 (2021)

    2021

  27. [27]

    Garsed, D. W. et al. The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer. Nat Genet 54 , 1853–1864 (2022)

    2022

  28. [28]

    Newell, F. et al. Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell 40 , 88–102.e7 (2022)

    2022

  29. [29]

    Liu, T. et al. High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39CD8 T cells. Gut 70 , 1965–1977 (2021)

    1965

  30. [30]

    Thibaudin, M. et al. First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial. Nat Med 29 , 2087–2098 (2023)

    2087

  31. [31]

    Nicholas, B. et al. Identification of neoantigens in oesophageal adenocarcinoma. Immunology 168 , 420–431 (2023)

    2023

  32. [32]

    Hashimoto, S. et al. Neoantigen prediction in human breast cancer using RNA sequencing data. Cancer Sci 112 , 465–475 (2021)

    2021

  33. [33]

    Zou, B. et al. Integrative Genomic Analyses of 1,145 Patient Samples Reveal New Biomarkers in Esophageal Squamous Cell Carcinoma. Front Mol Biosci 8 , 792779 (2021)

    2021

  34. [34]

    Álvarez-Prado, Á. F. et al. Immunogenomic analysis of human brain metastases reveals diverse immune landscapes across genetically distinct tumors. Cell Rep Med 4 , 100900 (2023)

    2023

  35. [35]

    Singhal, K. et al. ImmunoNX: a robust bioinformatics workflow to support personalized neoantigen vaccine trials. ArXiv (2025)

    2025

  36. [36]

    Xia, H. et al. pVACview: an interactive visualization tool for efficient neoantigen prioritization and selection. Genome Med 16 , 132 (2024)

    2024

  37. [37]

    & Dapic, I

    Kote, S., Pirog, A., Bedran, G., Alfaro, J. & Dapic, I. Mass Spectrometry-Based Identification of MHC-Associated Peptides. Cancers (Basel) 12 , (2020)

    2020

  38. [38]

    Cell Systems 11 , 42–48.e7 (2020)

    MHCflurry 2.0: Improved Pan-Allele Prediction of MHC Class I-Presented Peptides by Incorporating Antigen Processing. Cell Systems 11 , 42–48.e7 (2020)

    2020

  39. [39]

    NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data

    Birkir Reynisson , Bruno Alvarez , Sinu Paul , Bjoern Peters , Morten Nielsen. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Research (2020) doi:10.1093/nar/gkaa379

    work page doi:10.1093/nar/gkaa379 2020

  40. [40]

    Albert, B. A. et al. Deep neural networks predict class I major histocompatibility complex epitope presentation and transfer learn neoepitope immunogenicity. Nat Mach Intell 5 , 861–872 (2023)

    2023

  41. [41]

    Xia, H. et al. Computational prediction of MHC anchor locations guides neoantigen identification and prioritization. Sci Immunol 8 , eabg2200 (2023)

    2023

  42. [42]

    https://doi.org/10.1093/bib/bbab160 doi:10.1093/bib/bbab160

    Website. https://doi.org/10.1093/bib/bbab160 doi:10.1093/bib/bbab160

    work page doi:10.1093/bib/bbab160

  43. [43]

    Uhrig, S. et al. Accurate and efficient detection of gene fusions from RNA sequencing data. Genome Res 31 , 448–460 (2021)

    2021

  44. [44]

    Haas, B. J. et al. Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods. Genome Biology 20 , 213 (2019)

    2019

  45. [45]

    Cotto, K. C. et al. Integrated analysis of genomic and transcriptomic data for the discovery of splice-associated variants in cancer. Nat Commun 14 , 1589 (2023)

    2023

  46. [46]

    https://doi.org/10.1101/142919 doi:10.1101/142919

    Website. https://doi.org/10.1101/142919 doi:10.1101/142919

    work page doi:10.1101/142919

  47. [47]

    Redox Biology 42 , 101901 (2021)

    Protein oxidation - Formation mechanisms, detection and relevance as biomarkers in human diseases. Redox Biology 42 , 101901 (2021)

    2021

  48. [48]

    Ishizuka, A. S. et al. Improving peptide vaccine manufacturability without sacrificing immunogenicity: substitution of methionine and cysteine with oxidation-resistant isosteres. bioRxiv (2026) doi:10.64898/2026.01.20.699901

    work page doi:10.64898/2026.01.20.699901 2026

  49. [49]

    Wang, J. et al. Mechanistic Study of Diketopiperazine Formation during Solid-Phase Peptide Synthesis of Tirzepatide. ACS Omega 7 , 46809–46824 (2022)

    2022

  50. [50]

    Peptide Design: Principles & Methods. thermofisher.com https://www.thermofisher.com/us/en/home/life-science/protein-biology/protein-biology-learni ng-center/protein-biology-resource-library/pierce-protein-methods/peptide-design.html#:~:te xt=N%2Dterminal%20glutamine%20is%20unstable,peptide%20synthesis%2C%20resulting %20in%20deletions

  51. [51]

    & Clarke, S

    Geiger, T. & Clarke, S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J Biol Chem 262 , 785–794 (1987)

    1987

  52. [52]

    Lynn, G. M. et al. Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens. Nat Biotechnol 38 , 320–332 (2020)

    2020

  53. [53]

    Hailemichael, Y. et al. Persistent antigen at vaccination sites induces tumor-specific CD8 + T cell sequestration, dysfunction and deletion. Nat Med 19 , 465–472 (2013)

    2013

  54. [54]

    https://doi.org/10.3390/separations12020036 doi:10.3390/separations12020036

    Website. https://doi.org/10.3390/separations12020036 doi:10.3390/separations12020036

    work page doi:10.3390/separations12020036

  55. [55]

    Verganti, S. et al. Use of Oncept melanoma vaccine in 69 canine oral malignant melanomas in the UK. J Small Anim Pract 58 , 10–16 (2017)

    2017

  56. [56]

    Flesner, B. K. et al. Autologous cancer cell vaccination, adoptive T-cell transfer, and interleukin-2 administration results in long-term survival for companion dogs with osteosarcoma. J Vet Intern Med 34 , 2056–2067 (2020)

    2056

  57. [57]

    Glikin, G. C. & Finocchiaro, L. M. E. Clinical Trials of Cancer Immunogene Therapies in Companion Animals: An Update (2017-2024). Vet Sci 12 , (2025)

    2017

  58. [58]

    Doyle, H. A. et al. Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer. Transl Oncol 14 , 101205 (2021)

    2021

  59. [59]

    Schaettler, M. O. et al. Characterization of the Genomic and Immunologic Diversity of Malignant Brain Tumors through Multisector Analysis. Cancer Discov 12 , 154–171 (2022)

    2022

  60. [60]

    The GTEx Consortium atlas of genetic regulatory effects across human tissues

    GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 369 , 1318–1330 (2020)

    2020

  61. [61]

    Matsushita, H. et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482 , 400–404 (2012)

    2012

  62. [62]

    Yu, F. et al. Fast Quantitative Analysis of timsTOF PASEF Data with MSFragger and IonQuant. Mol Cell Proteomics 19 , 1575–1585 (2020)

    2020

  63. [63]

    Yu, F. et al. Analysis of DIA proteomics data using MSFragger-DIA and FragPipe computational platform. Nature Communications 14 , 4154 (2023)

    2023

  64. [64]

    Kaabinejadian, S. et al. Accurate MHC Motif Deconvolution of Immunopeptidomics Data Reveals a Significant Contribution of DRB3, 4 and 5 to the Total DR Immunopeptidome. Front Immunol 13 , 835454 (2022)

    2022

  65. [65]

    Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515 , 577–581 (2014)

    2014

  66. [66]

    Fehlings, M. et al. Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8 T cells. Nat Commun 8 , 562 (2017)

    2017

  67. [67]

    Shankaran, V. et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 , 1107–1111 (2001)

    2001

  68. [68]

    Zhang, Z. et al. : Identification of personalized alternative splicing based neoantigens with RNA-seq. Aging (Albany NY) 12 , 14633–14648 (2020)

    2020

  69. [69]

    Pan, Y. et al. IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing. Proc Natl Acad Sci U S A 120 , e2221116120 (2023)

    2023

  70. [70]

    Trincado, J. L. et al. ISOTOPE: ISOform-guided prediction of epiTOPEs in cancer. PLoS Comput Biol 17 , e1009411 (2021)

    2021

  71. [71]

    Chai, S. et al. NeoSplice: a bioinformatics method for prediction of splice variant neoantigens. Bioinform Adv 2 , vbac032 (2022)

    2022

  72. [72]

    Li, G. et al. Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy. Sci Transl Med 16 , eade2886 (2024)

    2024

  73. [73]

    Lang, F. et al. Prediction of tumor-specific splicing from somatic mutations as a source of neoantigen candidates. Bioinform Adv 4 , vbae080 (2024)

    2024

  74. [74]

    Palmer, T. et al. SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors. Cancer Res Commun 4 , 3137–3150 (2024)

    2024

  75. [75]

    Wickland, D. P. et al. Comprehensive profiling of cancer neoantigens from aberrant RNA splicing. J Immunother Cancer 12 , (2024)

    2024

  76. [76]

    Liu, C. et al. ProGeo-Neo v2.0: A One-Stop Software for Neoantigen Prediction and Filtering Based on the Proteogenomics Strategy. Genes (Basel) 13 , (2022)

    2022

  77. [77]

    Huber, F. et al. A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy. Nat Biotechnol 43 , 1360–1372 (2025)

    2025

  78. [78]

    & Zhang, B

    Wen, B., Li, K., Zhang, Y. & Zhang, B. Cancer neoantigen prioritization through sensitive and reliable proteogenomics analysis. Nature Communications 11 , 1759 (2020)

    2020

  79. [79]

    & Lemieux, S

    Daouda, T., Perreault, C. & Lemieux, S. pyGeno: A Python package for precision medicine and proteogenomics. F1000Res 5 , 381 (2016)

    2016

  80. [80]

    J., Dick, I

    Redwood, A. J., Dick, I. M., Creaney, J. & Robinson, B. W. S. What’s next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination. Oncoimmunology 11 , 2038403 (2022)

    2022